Healthcare | March 22, 2022
M2 milk platform to develop cell-cultured milk
Building the future of food in the birthplace of cell-cultured milk
Building the future of food in the birthplace of cell-cultured milk
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
Data published in the prestigious journal ACS Central Science of the American Chemical Society
Moving well beyond the traditional approach of testing a vaccine’s collective response in large populations, this precision approach can identify how an individual’s own immune system responds to a vaccine, offering an unprecedented opportunity to measure vaccine safety and effectiveness
Spread over 43,000 square feet, the facility will be set up to cater to the increasing demand for transformative molecular testing in India and across the world for early and accurate diagnosis
Under the agreement, Lonza will deliver cGMP-standard drug substance for clinical supply
Biolexis will also leverage the capabilities of Strides Group for launching this vaccine across regions where the group has a deep market presence and established relationships
_256_384.jpg)
The Indian companies that have been granted licences are Cipla, Sun Pharma, Laurus Labs, Divis Labs, Glenmark, Cadila, Torrent, Emcure, McLeods, SMS Pharmaceuticals, Strides, Biocon, Aurobindo Pharma, Hetero, Granules, Amneal, MSN, Arene Life Sciences and Viatris
EUROAPI listing on Euronext Paris will occur in H1 2022, despite volatile market conditions
DASH enables non-laboratory personnel to insert a nasal swab specimen directly into our test cartridge and then load the cartridge into the DASH instrument, providing an accurate result in about 15 minutes
Subscribe To Our Newsletter & Stay Updated
